Carvedilol Uses, Dosage, Side Effects & Warnings | DrugsAtlas
Authoritative Clinical Reference
DRUG NAME: Carvedilol
Therapeutic Class: Beta-blocker
Subclass: Combined Alpha-Beta Blocker
Speciality: Cardiology
Subclass: Combined Alpha-Beta Blocker
Speciality: Cardiology
Schedule (India): H
Route(s): Oral
Route(s): Oral
Formulations Available in India:
- Tablets: 3.125 mg, 6.25 mg, 12.5 mg, 25 mg
- Controlled-release (CR) tablets: 10 mg, 20 mg, 40 mg (limited availability; not all brands)
INDICATIONS + DOSING — FOR CLINICIAN USE ONLY
Primary Indications (Approved / Standard in India)
1. Hypertension (mild to moderate)
| Parameter | Detail |
|---|---|
|
Starting dose
|
6.25 mg twice daily |
|
Titration
|
Increase by 6.25 mg per dose every 1–2 weeks, guided by blood pressure response |
|
Usual maintenance dose
|
12.5–25 mg twice daily |
|
Maximum dose
|
50 mg/day (in 2 divided doses) |
- Key clinical notes:
-
- Administer with food to slow absorption and reduce risk of orthostatic hypotension
- Use lower starting dose (3.125 mg twice daily) in volume-depleted patients or those on diuretics
- Do not withdraw abruptly — taper over 1–2 weeks to avoid rebound tachycardia, angina, or hypertensive crisis
- Alpha-to-beta blockade ratio is approximately 1:2 to 1:3
2. Chronic Heart Failure with Reduced Ejection Fraction (NYHA Class II–IV)
| Parameter | Detail |
|---|---|
|
Starting dose
|
3.125 mg twice daily |
|
Titration
|
Double the dose at intervals of not less than 2 weeks, as tolerated |
|
Usual maintenance dose
|
25 mg twice daily (body weight <85 kg); 50 mg twice daily (body weight ≥85 kg) |
|
Maximum dose
|
50 mg twice daily |
- Key clinical notes:
-
- Patient must be clinically stable (no fluid overload requiring IV diuretics, no recent ICU admission) before initiation
- Administer with food — essential for consistent absorption and to reduce orthostatic hypotension
- Monitor weight, orthostatic BP, heart rate, serum creatinine, and symptoms at each dose increase
- Temporary worsening of heart failure symptoms may occur during up-titration — manage with diuretic adjustment rather than stopping carvedilol unless severe
- Proven mortality benefit in chronic HFrEF (COPERNICUS, COMET trials)
- NYHA IV patients: initiate only under specialist supervision with close monitoring
3. Chronic Stable Angina
| Parameter | Detail |
|---|---|
|
Starting dose
|
12.5 mg twice daily |
|
Titration
|
Increase to 25 mg twice daily after 2 weeks if needed and tolerated |
|
Usual maintenance dose
|
25 mg twice daily |
|
Maximum dose
|
50 mg/day |
- Key clinical notes:
-
- Administer with food
- Assess anti-anginal response (exercise tolerance, frequency of angina episodes)
- Do not withdraw abruptly
4. Post-Myocardial Infarction with Left Ventricular Dysfunction (EF ≤40%)
| Parameter | Detail |
|---|---|
|
Starting dose
|
6.25 mg twice daily |
|
Titration
|
Increase to 12.5 mg twice daily after 3–10 days, then to 25 mg twice daily as tolerated |
|
Usual maintenance dose
|
25 mg twice daily |
|
Maximum dose
|
50 mg/day |
- Key clinical notes:
-
- Initiate when patient is haemodynamically stable (no acute decompensation, SBP ≥100 mmHg, HR >50 bpm)
- Administer with food
- Based on CAPRICORN trial evidence — demonstrated reduction in all-cause mortality and recurrent non-fatal MI
- Continue as long-term therapy unless contraindicated
Secondary Indications — Adults Only (Off-label)
| Indication | Dose | Duration | Notes |
|---|---|---|---|
|
Portal hypertension in cirrhosis — OFF-LABEL
|
Starting dose: 3.125–6.25 mg once daily; titrate cautiously to max 12.5 mg/day | Long-term | Specialist only (hepatologist/gastroenterologist). Maintain SBP >90 mmHg and resting HR >55 bpm. Superior to propranolol in reducing HVPG in several studies including Indian trials. Avoid in Child-Pugh C or refractory ascites. Evidence: Indian hepatology practice (AIIMS, PGI Chandigarh studies); RCTs demonstrating greater HVPG reduction vs propranolol. |
|
Atrial fibrillation — rate control in HF patients — OFF-LABEL
|
As per heart failure dosing above | Long-term as part of HF management | Specialist only (cardiology). Beta-blocking effect provides rate control; commonly used in HF-AF overlap. Evidence: Indian and international cardiology practice; sub-group analyses of COMET, AF-CHF trials. |
PAEDIATRIC DOSING (Specialist Only)
⚠️ No approved paediatric indication exists in India. All paediatric use is off-label and must be initiated only under paediatric cardiologist supervision.
⚠️ Not recommended below 2 years of age except under direct specialist supervision at a tertiary care centre.
Primary Indications (Approved / Standard in India)
Not applicable — no approved paediatric indications in India.
Secondary Indications — Paediatric Doses (Off-label)
1. Paediatric heart failure (e.g., dilated cardiomyopathy) — OFF-LABEL
| Parameter | Detail |
|---|---|
|
Starting dose
|
0.05 mg/kg/dose twice daily |
|
Titration
|
Increase by 0.05–0.1 mg/kg/dose every 1–2 weeks if tolerated |
|
Usual maintenance dose
|
0.1–0.5 mg/kg/dose twice daily (total: 0.2–1 mg/kg/day) |
|
Maximum dose
|
0.4 mg/kg/dose twice daily (do not exceed adult maximum) |
- Specialist only — paediatric cardiologist
- Evidence: Limited; Indian paediatric cardiology centre experience, small international paediatric trials
- Safety monitoring: Heart rate, blood pressure (including orthostatic), weight, LFTs, renal function, blood glucose
- Administer with food
2. Portal hypertension in paediatric cirrhosis — OFF-LABEL
| Parameter | Detail |
|---|---|
|
Starting dose
|
0.05 mg/kg once daily |
|
Titration
|
Very cautious; titrate based on HR and BP |
|
Maximum dose
|
0.1 mg/kg twice daily (specialist discretion) |
- Specialist only — paediatric hepatologist/gastroenterologist
- Monitor: HR (maintain >60 bpm), BP, LFTs
- Evidence: Extremely limited; extrapolated from adult data and isolated case series
RENAL ADJUSTMENT
| Renal Function | Recommendation |
|---|---|
| Mild-moderate impairment (eGFR 30–89) | No dose adjustment required |
| Severe impairment (eGFR <30) | Use with caution; no specific dose reduction recommended but monitor closely for bradycardia, hypotension, and fluid retention |
| Haemodialysis | No supplemental dose required; carvedilol is highly protein-bound and not significantly dialysed |
HEPATIC ADJUSTMENT
| Severity | Recommendation |
|---|---|
|
Mild impairment
|
Use with caution; initiate at the lowest dose; monitor LFTs |
|
Moderate impairment
|
Reduce dose; slower titration; monitor LFTs and clinical status closely; first-pass metabolism is reduced, leading to higher bioavailability |
|
Severe impairment
|
Contraindicated. Carvedilol undergoes extensive hepatic metabolism; bioavailability increases markedly. Risk of severe hypotension and accumulation.
|
CONTRAINDICATIONS
- Bronchial asthma or clinically significant bronchospastic disease
- Second- or third-degree atrioventricular block (without functioning pacemaker)
- Sick sinus syndrome (without functioning pacemaker)
- Severe sinus bradycardia (<50 bpm)
- Cardiogenic shock
- Decompensated heart failure requiring intravenous inotropic support (acute phase)
- Severe hepatic impairment (Child-Pugh C)
- Known hypersensitivity to carvedilol or any excipient
CAUTIONS
- Diabetes mellitus — may mask tachycardia and adrenergic symptoms of hypoglycaemia (sweating is preserved); however, carvedilol has a more favourable metabolic profile compared to non-vasodilating beta-blockers
- Peripheral vascular disease — may worsen claudication symptoms
- Thyrotoxicosis — may mask tachycardia; do not use as sole treatment for thyrotoxicosis
- Chronic obstructive pulmonary disease (COPD) — use with caution; preferably under respiratory monitoring; generally better tolerated than non-selective pure beta-blockers due to alpha-blocking vasodilatory effect
- Pheochromocytoma — although carvedilol has alpha-blocking activity, the beta:alpha ratio may be insufficient; ensure adequate dedicated alpha-blockade (e.g., phenoxybenzamine) before use
- First-dose orthostatic hypotension — especially with concomitant diuretics or volume depletion; ensure patient is seated for at least 1 hour after first dose
- History of severe anaphylaxis — beta-blockers may reduce effectiveness of adrenaline in anaphylaxis management
- Concurrent non-dihydropyridine calcium channel blockers (verapamil/diltiazem) — risk of severe bradycardia or AV block
- Prinzmetal (vasospastic) angina — beta-blockade may theoretically worsen coronary vasospasm
- Abrupt withdrawal — may precipitate rebound angina, MI, or arrhythmia; always taper over 1–2 weeks
- Contact lens wearers — may reduce lacrimation
PREGNANCY
| Parameter | Detail |
|---|---|
|
Overall safety statement
|
Limited data; use only if potential benefit clearly outweighs risk to the fetus |
|
Risk category
|
Not classified as safe in pregnancy; beta-blockers as a class carry risk of IUGR, neonatal bradycardia, and hypoglycaemia |
|
Preferred alternatives
|
Labetalol (first-line beta-blocker in pregnancy), methyldopa, nifedipine — per Indian obstetric guidelines |
|
When to use
|
Only when preferred alternatives are unsuitable or unavailable; under specialist obstetric/cardiology supervision |
|
Maternal monitoring
|
Blood pressure, heart rate |
|
Fetal monitoring
|
Fetal heart rate monitoring, serial growth scans (risk of IUGR with chronic beta-blocker exposure) |
|
Near delivery
|
Monitor neonate for at least 48–72 hours after delivery for bradycardia, hypotension, hypoglycaemia, and respiratory depression |
LACTATION
| Parameter | Detail |
|---|---|
|
Breastfeeding compatibility
|
Insufficient data — extent of excretion into human breast milk is not well characterised |
|
Drug levels in milk
|
Not clearly established; expected to be present based on pharmacological properties (high lipophilicity, moderate protein binding) |
|
Preferred alternatives
|
Labetalol, metoprolol (more established safety data during breastfeeding in Indian practice) |
|
Infant monitoring
|
If used: observe for bradycardia, poor feeding, excessive drowsiness, and inadequate weight gain |
|
Recommendation
|
Use only if no suitable alternative available; specialist input advised |
ELDERLY
- Recommended starting dose: 3.125 mg twice daily (for all indications)
- Titration: Slower than in younger adults; increase at intervals of no less than 2 weeks; assess standing BP before each dose increase
- Extra risks:
-
- Orthostatic hypotension and syncope — particularly with first dose and during up-titration
- Falls and related injury (hip fractures)
- Reduced hepatic clearance — bioavailability may be 50% higher in elderly patients
- Blunted compensatory heart rate response — increased bradycardia risk
- Masked hypoglycaemia in elderly diabetics
- Monitoring: Orthostatic BP at each visit, heart rate, renal function, body weight (in HF), blood glucose (if diabetic)
MAJOR DRUG INTERACTIONS
| Interacting Drug/Class | Mechanism / Risk | Action |
|---|---|---|
|
Verapamil, Diltiazem (non-dihydropyridine CCBs)
|
Additive negative chronotropy and dromotropy; risk of severe bradycardia, AV block, or cardiac arrest |
Avoid combination; if essential, use only with continuous ECG monitoring
|
|
Amiodarone
|
Additive bradycardia and AV conduction delay; amiodarone also inhibits CYP2D6 increasing carvedilol levels |
Avoid or use with extreme caution; monitor HR and ECG closely
|
|
Clonidine
|
If clonidine is withdrawn while patient is on carvedilol, risk of severe rebound hypertension (beta-blockade prevents compensatory vasodilation) |
If both used: withdraw carvedilol first (taper over 1–2 weeks), then taper clonidine over several days
|
|
CYP2D6 inhibitors (fluoxetine, paroxetine, quinidine)
|
Carvedilol is a CYP2D6 substrate; inhibition leads to significantly increased plasma levels and risk of excessive beta-/alpha-blockade |
Monitor HR and BP closely; consider dose reduction of carvedilol
|
|
Rifampicin
|
Potent CYP inducer (CYP2C9, CYP1A2, P-glycoprotein); may reduce carvedilol plasma levels by up to 60% |
Monitor BP; may need significant carvedilol dose increase during concurrent rifampicin; reassess when rifampicin stopped
|
|
General anaesthetics (halothane, enflurane, etc.)
|
Additive myocardial depression and hypotension |
Inform anaesthetist; do not abruptly stop carvedilol before surgery
|
|
MAOIs (non-selective)
|
Risk of exaggerated hypotensive or hypertensive response |
Avoid combination
|
MODERATE DRUG INTERACTIONS
| Interacting Drug/Class | Mechanism / Risk | Action |
|---|---|---|
|
Digoxin
|
Carvedilol increases digoxin levels by ~15–20% (P-glycoprotein inhibition); additive bradycardia | Monitor serum digoxin levels and HR; adjust digoxin dose if needed |
|
Insulin, Sulphonylureas
|
May mask adrenergic warning signs of hypoglycaemia (tachycardia, tremor); sweating is preserved | Counsel patient; monitor blood glucose more frequently |
|
Other antihypertensives (ACEIs, ARBs, diuretics)
|
Additive hypotension | Adjust doses; monitor BP and volume status |
|
NSAIDs (ibuprofen, diclofenac, etc.)
|
May attenuate antihypertensive effect (renal prostaglandin inhibition) | Monitor BP if concurrent long-term NSAID use |
|
Cimetidine
|
Inhibits hepatic metabolism of carvedilol; may increase bioavailability by ~30% | Monitor for excessive bradycardia/hypotension; consider dose reduction or switch to ranitidine/PPI |
|
Tricyclic antidepressants (amitriptyline, imipramine)
|
Potentiation of orthostatic hypotension | Use with caution; monitor for postural symptoms |
|
Cyclosporine
|
Carvedilol may increase cyclosporine levels (inhibition of P-glycoprotein) | Monitor cyclosporine trough levels closely |
COMMON ADVERSE EFFECTS
- Dizziness
- Fatigue / tiredness
- Orthostatic hypotension (especially during titration and with first dose)
- Bradycardia
- Weight gain (particularly in heart failure patients — may also indicate fluid retention)
- Diarrhoea
- Nausea
- Cold extremities
- Visual disturbance (blurred vision)
- Oedema (peripheral)
Note: Unlike traditional non-vasodilating beta-blockers (atenolol, metoprolol), carvedilol has a more favourable metabolic profile — lower incidence of new-onset diabetes and less worsening of glycaemic control (GEMINI trial evidence).
SERIOUS ADVERSE EFFECTS
| Adverse Effect | Clinical Significance |
|---|---|
|
Severe bradycardia / high-degree AV block
|
May require IV atropine or temporary pacing; discontinue carvedilol |
|
Heart failure exacerbation / acute decompensation
|
Particularly during initiation or up-titration; manage with diuretic adjustment; withhold or reduce dose if severe |
|
Hepatotoxicity (rare; reversible elevation of transaminases, very rarely fulminant hepatic injury)
|
Monitor LFTs if unexplained symptoms (jaundice, malaise, dark urine, pruritus); discontinue immediately if ALT/AST >3× ULN with symptoms
|
|
Bronchospasm
|
In patients with underlying airway disease or undiagnosed reactive airways; may require bronchodilator therapy and drug discontinuation |
|
Severe hypotension / syncope
|
Especially with first dose, volume depletion, or concurrent vasodilators |
|
Stevens-Johnson Syndrome / toxic epidermal necrolysis
|
Extremely rare; isolated case reports only; discontinue immediately if mucocutaneous reaction suspected
|
MONITORING REQUIREMENTS
| Timing | Parameters |
|---|---|
|
Baseline
|
Blood pressure (sitting and standing), heart rate, ECG, body weight, LFTs, renal function, blood glucose and HbA1c (in diabetics), echocardiography (in HF patients) |
|
After initiation / each dose titration
|
BP (sitting and standing) and HR — assess before next dose increase; weight (HF patients — at each visit); symptoms of orthostatic hypotension, fatigue, worsening dyspnoea |
|
Heart failure — first 3 months
|
Weight, fluid status, symptoms at every 2-week visit during up-titration; renal function, electrolytes at 1–2 weeks and after each major dose change |
|
Long-term (chronic use)
|
BP, HR, weight at every visit; LFTs every 6–12 months; renal function and electrolytes every 6 months; blood glucose periodically in diabetics; echocardiography annually in HF |
BRANDS AVAILABLE IN INDIA
| Brand name | Manufacturer | Available strengths |
|---|---|---|
| Cardivas | Sun Pharmaceutical | 3.125mg, 6.25mg, 12.5mg, 25mg |
| Carloc | Cipla | 3.125mg, 6.25mg, 12.5mg, 25mg |
| Carca | Micro Labs | 3.125mg, 6.25mg, 12.5mg, 25mg |
| Carvipress | Lupin | 3.125mg, 6.25mg, 12.5mg, 25mg |
| Carvedilol (Generic) | Multiple Indian manufacturers | 3.125mg, 6.25mg, 12.5mg, 25mg |
| FDCs | Carvedilol + Hydrochlorothiazide combinations are available from some manufacturers | _ |
PRICE RANGE (INR)
| Formulation | Approximate Price Range | Notes |
|---|---|---|
| Tablet 3.125 mg | ₹2–5 per tablet | Varies by brand |
| Tablet 6.25 mg | ₹2–6 per tablet | Varies by brand |
| Tablet 12.5 mg | ₹3–8 per tablet | Varies by brand |
| Tablet 25 mg | ₹5–12 per tablet | Varies by brand |
|
NLEM status
|
Listed in NLEM 2022
|
NPPA ceiling price may apply for scheduled formulations; generics widely available at lower cost; government supply at subsidised rates |
CLINICAL PEARLS
- "Start low, go slow" is paramount in heart failure — initiate at 3.125 mg twice daily and double every 2 weeks only if the patient remains stable; target the maximum tolerated dose, not the maximum possible dose.
- Always administer with food — this slows absorption, reduces peak plasma levels, and significantly decreases the risk of orthostatic hypotension (bioavailability increases by ~25% with food, but rate of absorption decreases, providing a smoother haemodynamic effect).
- Metabolic advantage over atenolol and metoprolol — the GEMINI trial demonstrated that carvedilol does not worsen glycaemic control (HbA1c) and may improve insulin sensitivity, making it the preferred beta-blocker in heart failure or hypertension patients with concurrent diabetes or metabolic syndrome.
- Do not confuse transient HF worsening during up-titration with treatment failure — mild increase in weight (1–2 kg) or dyspnoea during titration can usually be managed by adjusting diuretic doses rather than discontinuing carvedilol.
- In portal hypertension, carvedilol reduces portal pressure more effectively than propranolol (due to additional anti-alpha-1 effect reducing intrahepatic resistance), but its use is limited by systemic hypotension in advanced cirrhosis — avoid in Child-Pugh C, refractory ascites, or SBP <90 mmHg.
- Not the preferred beta-blocker in pregnancy — labetalol has significantly more safety data in obstetric use; reserve carvedilol for non-pregnant populations unless no alternative exists.
TAGS
carvedilol; beta-blocker; combined alpha-beta blocker; heart failure; HFrEF; hypertension; post-MI; portal hypertension; NLEM India; cardiology; pregnancy-caution
VERSION
RxIndia v0.5 — 18 Feb 2026
REFERENCES
- CDSCO-approved prescribing information for carvedilol
- Indian Pharmacopoeia
- National List of Essential Medicines (NLEM) 2022, Ministry of Health & Family Welfare, Government of India
- API Textbook of Medicine
- AIIMS Treatment Protocols (Cardiology, Heart Failure)
- ICMR Guidelines on Heart Failure Management
- Cardiological Society of India — Practice Guidelines on Heart Failure
- IAP Guidelines (supportive reference for paediatric off-label use)
- Goodman & Gilman's The Pharmacological Basis of Therapeutics (pharmacology reference)
- Key RCTs referenced: COPERNICUS, COMET, CAPRICORN, GEMINI (for evidence-based dosing and metabolic profile data)
- Indian hepatology studies on carvedilol in portal hypertension (AIIMS, PGI Chandigarh)
⚖️
Clinical Responsibility
This platform is designed strictly for healthcare professionals. Data provided is synthesized from authoritative pharmacological sources and clinical registries. Do not use for consumer medical decisions. Always verify critical dosing and contraindications with official institutional protocols and peer-reviewed journals.
Content Feedback
Is this information helpful?
Help us improve our clinical database for the medical community.